Evidence map›Paper›PMID 39621288›Full record

ArticleCardiovascular engineering and technology2025

Fluid Dynamic and in Vitro Blood Study to Understand Catheter-Related Thrombosis.

Hannah Palahnuk, Boyang Su, Thaddeus Harbaugh, Cleo Gesenberg, Shouhao Zhou, Elias Rizk, Jonathan Bernstein, S Will Hazard, Keefe B Manning

Abstract read
In one paragraph

Article in Cardiovascular engineering and technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hannah PalahnukDepartment of Biomedical Engineering, The Pennsylvania State University, 122 Chemical and Biomedical Engineering Building, University Park, PA, USA.
Boyang SuDepartment of Biomedical Engineering, The Pennsylvania State University, 122 Chemical and Biomedical Engineering Building, University Park, PA, USA.
Thaddeus HarbaughDepartment of Neurosurgery, Penn State College of Medicine, Hershey, PA, USA.
Cleo GesenbergDepartment of Biology, The Pennsylvania State University, University Park, PA, USA.
Shouhao ZhouDivision of Biostatistics and Bioinformatics, Penn State College of Medicine, Hershey, PA, USA.
Elias RizkDepartment of Neurosurgery, Penn State College of Medicine, Hershey, PA, USA.
Jonathan BernsteinDivision of Pediatric Hematology/Oncology, Penn State Hershey Children's Hospital, Hershey, PA, USA.
S Will HazardDepartment of Neurosurgery, Penn State College of Medicine, Hershey, PA, USA.
Keefe B ManningDepartment of Biomedical Engineering, The Pennsylvania State University, 122 Chemical and Biomedical Engineering Building, University Park, PA, USA. kbm10@psu.edu.ORCID 0000-0001-9029-5217

Funding

Penn State Clinical and Translational Science InstituteUL1TR002014 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KRASCHNEWSKI, JENNIFER L. · 2016 to 2025
$33.7M
NCATS NIH HHS UL1 TR002014
6 · The paper itself

Abstract

purposeCentral venous catheters (CVCs) provide a direct route to the venous circulation but are prone to catheter-related thrombosis (CRT). A known CRT risk factor is a high catheter-to-vein ratio (CVR), or a large catheter diameter with respect to the indwelling vein size. In this study, the CVR's effect on CVC hemodynamics and its impact on CRT is investigated with in vitro and in silico experiments.

methodsAn in vitro flow loop is used to characterize the hemodynamics around CVCs using particle image velocimetry. In addition, CRT is investigated using an in vitro flow loop with human blood and clinical catheters. The wall shear rate of flow around the CVC is computed numerically. CVRs of 0.20, 0.33, and 0.49 and Reynolds numbers of 200, 800, and 1300 are evaluated. No flow is used through CVC lumens to model chronic indwelling catheters.

resultsResults show CVR ≥ 0.33 promotes platelet-rich clot growth at the device tip and at an increased rate compared to lower CVR cases. A high wall shear rate gradient on the CVC tip and an extended wake distal to the tip exists for higher CVR cases, promoting the aggregation of platelets and subsequent stagnation for clot formation. Further, the combination of the CVR and Reynolds number are crucial to CRT potential, not the CVR alone. Specifically, thrombosis risk is increased with low (stasis driven) and/or high (platelet activation driven) flow conditions, with the CVR and CVC's geometry playing an additional role in promoting fluid mechanic driven thrombus development. A high CVR (≥ 0.33) and high flow condition (≥ 1300) results in the highest risk for clot growth at the tip of the device; other locations of the device are at risk for thrombus development in lower flow conditions, regardless of the CVR. The importance of the device geometry and flow in promoting thrombus and fibrin sheath formation is also shown for the device investigated.

conclusionsThis work demonstrates that the CVR, flow, and device geometry affect CRT. For clinical cases with CVR ≥ 0.33 and/or Re ≥ 1300, the device tip may be monitored more consistently for clot formation. Thrombosis risks remain on the entire catheter, regardless of the flow condition, for a CVR = 0.49. Device placement should be chosen carefully with respect to the combination of the Reynolds number and CVR. Further study is needed on the effect of catheterization to confirm these findings.

Indexed as

Blood CoagulationCatheterization, Central VenousCatheters, IndwellingCentral Venous CathetersHemodynamicsModels, CardiovascularThrombosisBlood Flow VelocityComputer SimulationEquipment DesignHemorheologyHumansRisk FactorsStress, MechanicalCentral venous catheterClottingFibrin sheathHemodynamicsSuperior vena cavaVenous access

Identifiers

PMID39621288
PMCPMC11904432

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.